Merck passes on KalVista DME candidate

KalVista Pharmaceuticals (NASDAQ:KALV) announces that its option agreement with Merck (NYSE:MRK) related to KVD001, its candidate for the potential treatment of diabetic macular edema (DME), and future oral DME molecules has expired.